140 related articles for article (PubMed ID: 37082866)
1. Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.
Ilg MM; Ralph DJ; Cellek S
J Sex Med; 2023 Jun; 20(7):925-934. PubMed ID: 37082866
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.
Ilg MM; Stafford SJ; Mateus M; Bustin SA; Carpenter MJ; Muneer A; Bivalacqua TJ; Ralph DJ; Cellek S
J Sex Med; 2020 Oct; 17(10):1848-1864. PubMed ID: 32771352
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease.
Mateus M; Ilg MM; Stebbeds WJ; Christopher N; Muneer A; Ralph DJ; Cellek S
J Sex Med; 2018 Jul; 15(7):947-957. PubMed ID: 29891411
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation.
Milenkovic U; Ilg MM; Zuccato C; Ramazani Y; De Ridder D; Albersen M
BJU Int; 2019 Apr; 123(4):703-715. PubMed ID: 30536599
[TBL] [Abstract][Full Text] [Related]
6. A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals.
Cellek S; Megson M; Ilg MM; Ralph DJ
J Sex Med; 2023 Jul; 20(8):1057-1059. PubMed ID: 37524687
[No Abstract] [Full Text] [Related]
7. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
Ferrini MG; Kovanecz I; Nolazco G; Rajfer J; Gonzalez-Cadavid NF
BJU Int; 2006 Mar; 97(3):625-33. PubMed ID: 16469038
[TBL] [Abstract][Full Text] [Related]
8. Impact of statins on cellular respiration and de-differentiation of myofibroblasts in human failing hearts.
Emelyanova L; Sra A; Schmuck EG; Raval AN; Downey FX; Jahangir A; Rizvi F; Ross GR
ESC Heart Fail; 2019 Oct; 6(5):1027-1040. PubMed ID: 31520523
[TBL] [Abstract][Full Text] [Related]
9. Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility.
Ilg MM; Harding S; Lapthorn AR; Kirvell S; Ralph DJ; Bustin SA; Ball G; Cellek S
J Sex Med; 2024 Mar; 21(4):278-287. PubMed ID: 38383071
[TBL] [Abstract][Full Text] [Related]
10. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
[TBL] [Abstract][Full Text] [Related]
11. The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.
Gelfand RA; Vernet D; Kovanecz I; Rajfer J; Gonzalez-Cadavid NF
J Sex Med; 2015 Feb; 12(2):313-27. PubMed ID: 25496134
[TBL] [Abstract][Full Text] [Related]
12. TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation.
Ilg MM; Bustin SA; Ralph DJ; Cellek S
Sci Rep; 2024 May; 14(1):12389. PubMed ID: 38811625
[TBL] [Abstract][Full Text] [Related]
13. Experimental models of Peyronie's disease. Implications for new therapies.
Gonzalez-Cadavid NF; Rajfer J
J Sex Med; 2009 Feb; 6(2):303-13. PubMed ID: 19138365
[TBL] [Abstract][Full Text] [Related]
14. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
[TBL] [Abstract][Full Text] [Related]
15. Profibrotic role of myostatin in Peyronie's disease.
Cantini LP; Ferrini MG; Vernet D; Magee TR; Qian A; Gelfand RA; Rajfer J; Gonzalez-Cadavid NF
J Sex Med; 2008 Jul; 5(7):1607-22. PubMed ID: 18422491
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
Zenzmaier C; Kern J; Sampson N; Heitz M; Plas E; Untergasser G; Berger P
Endocrinology; 2012 Nov; 153(11):5546-55. PubMed ID: 22948216
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.
Piao S; Choi MJ; Tumurbaatar M; Kim WJ; Jin HR; Shin SH; Tuvshintur B; Yin GN; Song JS; Kwon MH; Lee SJ; Han JY; Kim SJ; Ryu JK; Suh JK
J Sex Med; 2010 Oct; 7(10):3385-95. PubMed ID: 20233292
[TBL] [Abstract][Full Text] [Related]
18. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.
Davila HH; Ferrini MG; Rajfer J; Gonzalez-Cadavid NF
BJU Int; 2003 Jun; 91(9):830-8. PubMed ID: 12780843
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.
Ilg MM; Lapthorn AR; Ralph DJ; Cellek S
PLoS One; 2022; 17(12):e0277646. PubMed ID: 36508413
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
Gonzalez-Cadavid NF; Rajfer J
Nat Rev Urol; 2010 Apr; 7(4):215-21. PubMed ID: 20212516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
